ライフサイエンスコーパス: orthotopic liver transplantation

1 s are refractory to drug therapy and require orthotopic liver transplantation.

2 potentially fatal complication of piggyback orthotopic liver transplantation.

3 c venous outflow obstruction after piggyback orthotopic liver transplantation.

4 y section, especially in a center performing orthotopic liver transplantation.

5 perfusion injury still impact the outcome of orthotopic liver transplantation.

6 with outcome in HCV- and HCV+ recipients of orthotopic liver transplantation.

7 ogic CR; one HCC patient with a PR underwent orthotopic liver transplantation.

8 ed fatty Zucker rat model of I/R followed by orthotopic liver transplantation.

9 ter experience in the care of children after orthotopic liver transplantation.

10 r advanced liver disease, underwent isolated orthotopic liver transplantation.

11 cyclopropenone while on the waiting list for orthotopic liver transplantation.

12 ronic graft-versus-host disease (GVHD) after orthotopic liver transplantation.

13 stent removal was deferred until the time of orthotopic liver transplantation.

14 or VII deficiency, successfully treated with orthotopic liver transplantation.

15 tumors) is limited to surgical resection or orthotopic liver transplantation.

16 ctomy has not been previously reported after orthotopic liver transplantation.

17 es the number of deaths in patients awaiting orthotopic liver transplantation.

18 treatment by portal decompression, required orthotopic liver transplantation.

19 ed) recipient rats on days 2, 4, and 7 after orthotopic liver transplantation.

20 r other hepatic arterial complications after orthotopic liver transplantation.

21 ificantly different from that of whole-organ orthotopic liver transplantation.

22 ssion, and they were approved and listed for orthotopic liver transplantation.

23 n of serum tacrolimus level after successful orthotopic liver transplantation.

24 munodeficiency virus infection who underwent orthotopic liver transplantation.

25 Three patients have undergone orthotopic liver transplantation.

26 % of the pediatric population that undergoes orthotopic liver transplantation.

27 s performed in 25 patients who had undergone orthotopic liver transplantation.

28 ase in children and may lead to the need for orthotopic liver transplantation.

29 rolled, followed by 3 h of SNMP recovery and orthotopic liver transplantation.

30 er tissue for HGV-RNA in patients undergoing orthotopic liver transplantation.

31 lant day 16, the animals underwent syngeneic orthotopic liver transplantation.

32 ve children with monoclonal LPD complicating orthotopic liver transplantation.

33 s found in the portal vein at the time of an orthotopic liver transplantation.

34 y rats were used as donors and recipients of orthotopic liver transplantation.

35 ne) on the outcome of HCV patients following orthotopic liver transplantation.

36 ous resolution of the spur cell anemia after orthotopic liver transplantation.

37 ion injury and associated acute rejection in orthotopic liver transplantation.

38 ement of BM-HSCs in liver regeneration after orthotopic liver transplantation.

39 N-based treatment response in patients after orthotopic liver transplantation.

40 idence is needed to fully define the role of orthotopic liver transplantation.

41 eased risk for morbidity and mortality after orthotopic liver transplantation.

42 fy factors that predict HCC recurrence after orthotopic liver transplantation.

43 ard approaches to in situ anastomosis during orthotopic liver transplantation.

44 nced hepatic encephalopathy who are awaiting orthotopic liver transplantation.

45 that seen after isolated orthotopic heart or orthotopic liver transplantation.

46 of the PDCD1 SNP PD1.3 were associated with orthotopic liver transplantation.

47 including their management during and after orthotopic liver transplantation.

48 t both of bone marrow transplantation and of orthotopic liver transplantation.

49 ermia appears to be promising as a bridge to orthotopic liver transplantation.

50 nctional rate observed in marginal steatotic orthotopic liver transplantation.

51 llion people and is the major indication for orthotopic liver transplantations.

52 Forty-eight and 52 months after orthotopic liver transplantation, all surviving patients

53 ients who underwent chemoembolization before orthotopic liver transplantation and those who did not.

54 (HCC) recurrence and overall survival after orthotopic liver transplantation and to identify factors

55 patient spontaneously recovered, 1 required orthotopic liver transplantation, and 1 died.

56 were as follows: 28% recovered, 52% required orthotopic liver transplantation, and 20% died.

57 ts infected with hepatitis C virus following orthotopic liver transplantation, and investigation cont

58 Even though auxiliary partial orthotopic liver transplantation (APOLT) as a technique

59 hesized that operative site infections after orthotopic liver transplantation arise from bacteria in

60 association between BMI and waiting time for orthotopic liver transplantation as a surrogate marker f

61 severe multisystem manifestations underwent orthotopic liver transplantation at age 50 months for th

62 sity of Rochester Medical Center (URMC) with orthotopic liver transplantation between 1998-2008.

63 with results in 1,154 patients who underwent orthotopic liver transplantation but not chemoembolizati

64 Of the 1,154 patients who underwent orthotopic liver transplantation but not chemotherapy, 6

65 ty using the original equation suggests that orthotopic liver transplantation, by reversing the under

66 ients with hepatitis C virus (HCV) following orthotopic liver transplantation can lead to significant

67 rative cardiovascular risk stratification in orthotopic liver transplantation candidates has proven c

68 A prospective cohort study of 7906 orthotopic liver transplantations carried out between Ap

69 fication caused by chronic renal failure and orthotopic liver transplantation, dystrophic calcificati

70 ne green uptake, arterial ketone body ratio, orthotopic liver transplantation) experiments were condu

71 ase, we identified 54 patients who underwent orthotopic liver transplantation for cryptogenic cirrhos

72 Nine patients receiving orthotopic liver transplantation for end-stage HCV-relat

73 ents younger than 18 years of age undergoing orthotopic liver transplantation for end-stage liver dis

74 ntation for patients with primary (AL) or by orthotopic liver transplantation for familial (ATTR) amy

75 Orthotopic liver transplantation for HBV under combinati

76 Orthotopic liver transplantation for HCV is performed wi

77 on (RT in situ RCR) in hepatic tissue, after orthotopic liver transplantation for HCV-related liver d

78 Hepatitis C infection recurs after orthotopic liver transplantation for hepatitis C virus (

79 s operation, making it a safe alternative to orthotopic liver transplantation for patients with a wid

80 juvant radiotherapy, chemosensitization, and orthotopic liver transplantation for patients with opera

81 ur institution, nine patients have undergone orthotopic liver transplantation for symptomatic hepatic

82 The role of orthotopic liver transplantation for the treatment of be

83 esent the first series of patients receiving orthotopic liver transplantation for this condition.

84 tation, which is a less invasive method than orthotopic liver transplantation for treatment of metabo

85 vanced liver disease should be evaluated for orthotopic liver transplantation from a cadaver donor or

86 identification of a complicated course after orthotopic liver transplantation from deceased donors ar

87 18 measurements in routine diagnostics after orthotopic liver transplantation from deceased donors sh

88 hort-term complications within 10 days after orthotopic liver transplantation from deceased donors.

89 s and inflammatory markers in patients after orthotopic liver transplantation from deceased donors.

90 th male donors and from 4 male recipients of orthotopic liver transplantations from female donors.

91 dly in transplanted kidneys, and concomitant orthotopic liver transplantation has lately been perform

92 r failure from alcoholic cirrhosis underwent orthotopic liver transplantation; however, an intraopera

93 t animal models of hepatic warm ischemia and orthotopic liver transplantation (hypothermic ischemia).

94 lop rejection within the first 30 days after orthotopic liver transplantation if the patient did not

95 ent was by liver resection in 6 patients and orthotopic liver transplantation in 2.

96 ve repair can be performed safely along with orthotopic liver transplantation in carefully selected p

97 study was designed to analyze the outcome of orthotopic liver transplantation in compromised rat host

98 During orthotopic liver transplantation in humans, we observed

99 in of hepatocytes in sex-mismatched cases of orthotopic liver transplantation in longitudinally perfo

100 tients, steroid therapy in two patients, and orthotopic liver transplantation in one patient.

101 There is concern that repeat orthotopic liver transplantation in patients with hepati

102 igh frequency of spontaneous tolerance after orthotopic liver transplantation in rodents and on the p

103 Orthotopic liver transplantation in the mouse is a power

104 Despite the efficacy of orthotopic liver transplantation in the treatment of end

105 Kingdom (P=0.37, log-rank test) and isolated orthotopic liver transplantation in the United States (P

106 Orthotopic liver transplantation in the United States is

107 plasty procedure was used in 115 consecutive orthotopic liver transplantations, including six left la

108 aled NO (iNO; 80 ppm) to patients undergoing orthotopic liver transplantation inhibits hepatic IR inj

109 The piggyback technique of orthotopic liver transplantation is an attractive altern

110 N or FK and an identical steroid taper after orthotopic liver transplantation is associated with exce

111 Late graft dysfunction after orthotopic liver transplantation is commonly due to chro

112 Orthotopic liver transplantation is currently the only c

113 Orthotopic liver transplantation is effective and potent

114 th chronic hepatitis C virus infection after orthotopic liver transplantation is excellent, significa

115 nce that mTORi prevents HCC recurrence after orthotopic liver transplantation is only suggestive.

116 Orthotopic liver transplantation is possible even in the

117 Orthotopic liver transplantation is the only available t

118 Orthotopic liver transplantation is the only definitive

119 cirrhosis from long-standing, untreated BCS, orthotopic liver transplantation is the only hope of rel

120 Orthotopic liver transplantation is the only proven effe

121 Orthotopic liver transplantation is the treatment of cho

122 entified as a potential contraindication for orthotopic liver transplantation (LT) because of lower s

123 Nine proceeded to orthotopic liver transplantation (mean 74 days to transp

124 umented by means of pathologic inspection at orthotopic liver transplantation (median shunt duration,

125 Orthotopic liver transplantation might be applicable for

126 Setup of the orthotopic liver transplantation model comprises three m

127 Here we test this hypothesis in an optimized orthotopic liver transplantation model.

128 in IRI to liver grafts using a syngeneic rat orthotopic liver transplantation model.

129 uction and maintenance of tolerance in a rat orthotopic liver transplantation model.

130 She had undergone orthotopic liver transplantation (OLT) 15 months before

131 ilar cholangiocarcinoma (CCA) have undergone orthotopic liver transplantation (OLT) after neoadjuvant

132 in rat liver models of ex vivo perfusion and orthotopic liver transplantation (OLT) after prolonged p

133 itochondrial antibody (AMA) status and prior orthotopic liver transplantation (OLT) among the PBC pat

134 Fourteen patients with ALF who were awaiting orthotopic liver transplantation (OLT) and had increased

135 lic disorders are common complications after orthotopic liver transplantation (OLT) and may lead to i

136 inferior outcomes compared with the primary orthotopic liver transplantation (OLT) and raises concer

137 an Americans compared with other races after orthotopic liver transplantation (OLT) and whether race

138 nts who underwent evaluation, treatment, and orthotopic liver transplantation (OLT) at their institut

139 to preserve renal function in patients after orthotopic liver transplantation (OLT) based on estimate

140 Patients receiving orthotopic liver transplantation (OLT) because of type D

141 c) provide effective immunosuppression after orthotopic liver transplantation (OLT) but can cause ren

142 mining of intraoperative hemodynamic data in orthotopic liver transplantation (OLT) can aid in the pr

143 Orthotopic liver transplantation (OLT) can be a definiti

144 Orthotopic liver transplantation (OLT) can be lifesaving

145 with signs of portal hypertension undergoing orthotopic liver transplantation (OLT) carries potential

146 Early allograft rejection after orthotopic liver transplantation (OLT) currently require

147 In orthotopic liver transplantation (OLT) distinct causes o

148 is produced predominantly in the liver, and orthotopic liver transplantation (OLT) eliminates more t

149 During orthotopic liver transplantation (OLT) for acute liver f

150 Patients who undergo orthotopic liver transplantation (OLT) for Budd-Chiari s

151 ty-three HCV-positive patients who underwent orthotopic liver transplantation (OLT) for end-stage liv

152 During orthotopic liver transplantation (OLT) for fulminant hep

153 f HCV recurrence during the first year after orthotopic liver transplantation (OLT) for HCV-related c

154 Although orthotopic liver transplantation (OLT) frequently result

155 We report the results of orthotopic liver transplantation (OLT) from 33 such dono

156 In 13 patients orthotopic liver transplantation (OLT) had to be perform

157 Orthotopic liver transplantation (OLT) has been associat

158 The success of orthotopic liver transplantation (OLT) has been limited

159 ber of lesions that predict recurrence after orthotopic liver transplantation (OLT) has not been clea

160 ting diabetes mellitus (DM) on outcome after orthotopic liver transplantation (OLT) has not been well

161 e reported that minority patients undergoing orthotopic liver transplantation (OLT) have poorer survi

162 y and mortality in obese patients undergoing orthotopic liver transplantation (OLT) have produced con

163 on 2-5 cm or two to three lesions <3 cm) for orthotopic liver transplantation (OLT) in 30 patients as

164 d orthotopic heart transplantation (OHT) and orthotopic liver transplantation (OLT) in achieving long

165 ver disease (ALD) is a common indication for orthotopic liver transplantation (OLT) in adults.

166 successfully used as bridging therapy before orthotopic liver transplantation (OLT) in efforts to del

167 ransplant centers may be hesitant to perform orthotopic liver transplantation (OLT) in patients with

168 infection is the most common indication for orthotopic liver transplantation (OLT) in the United Sta

169 The most frequent reason for orthotopic liver transplantation (OLT) in the United Sta

170 ve previously shown that patients listed for orthotopic liver transplantation (OLT) in United Network

171 While orthotopic liver transplantation (OLT) is a durable life

172 s clearance of hepatitis C virus (HCV) after orthotopic liver transplantation (OLT) is a rare occurre

173 Thrombocytopenia after orthotopic liver transplantation (OLT) is a well recogni

174 Poor linear growth after pediatric orthotopic liver transplantation (OLT) is a well-describ

175 Orthotopic liver transplantation (OLT) is an effective t

176 Orthotopic liver transplantation (OLT) is an effective t

177 Orthotopic liver transplantation (OLT) is frequently com

178 The impact of ethnicity on outcomes after orthotopic liver transplantation (OLT) is unclear.

179 Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) is universal, oft

180 profile of chronic anemia in children after orthotopic liver transplantation (OLT) is unknown.

181 Orthotopic liver transplantation (OLT) is, at present, t

182 en-induced hepatotoxicity, prognosis without orthotopic liver transplantation (OLT) may be very poor.

183 recruitment and activation in rat syngeneic orthotopic liver transplantation (OLT) model.

184 Cavaplasty orthotopic liver transplantation (OLT) offers advantages

185 und (DUS) arterial abnormalities (DAA) after orthotopic liver transplantation (OLT) often represent a

186 Five months post-orthotopic liver transplantation (OLT) one of the patien

187 ine level 2.5 mg/dL or higher at the time of orthotopic liver transplantation (OLT) or who received d

188 osis and is a strong prognostic predictor of orthotopic liver transplantation (OLT) outcome.

189 context of liver failure negatively impacts orthotopic liver transplantation (OLT) outcomes.

190 trospectively reviewed 131 consecutive adult orthotopic liver transplantation (OLT) performed in 129

191 With early posttransplant bone loss, orthotopic liver transplantation (OLT) recipients experi

192 of late graft loss and long-term outcome in orthotopic liver transplantation (OLT) recipients.

193 Orthotopic liver transplantation (OLT) requires cold isc

194 Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) significantly acc

195 transplantation effectively denies access to orthotopic liver transplantation (OLT) to another candid

196 Orthotopic liver transplantation (OLT) treats the severe

197 1989 to December 1992, 834 adults underwent orthotopic liver transplantation (OLT) using tacrolimus

198 on on graft and patient survival rates after orthotopic liver transplantation (OLT) using the United

199 Orthotopic liver transplantation (OLT) was performed in

200 Orthotopic liver transplantation (OLT) was performed in

201 y, the records of 325 patients who underwent orthotopic liver transplantation (OLT) were reviewed.

202 We prospectively studied children after orthotopic liver transplantation (OLT) with hemoglobin l

203 t antithymocyte globulin (RATG) induction in orthotopic liver transplantation (OLT) with tacrolimus m

204 th hepatocellular carcinoma (HCC) listed for orthotopic liver transplantation (OLT) within and outsid

205 failure is the single leading indication for orthotopic liver transplantation (OLT) worldwide.

206 d by ex vivo reperfusion or transplantation (orthotopic liver transplantation (OLT)) using an anti-PS

207 pSmad 2/3 was seen as early as 24 days after orthotopic liver transplantation (OLT), although no othe

208 C virus (HCV) infection usually recurs after orthotopic liver transplantation (OLT), and most patient

209 on portal hypertension and implications for orthotopic liver transplantation (OLT), however, require

210 During orthotopic liver transplantation (OLT), it is standard p

211 In the context of orthotopic liver transplantation (OLT), renal dysfunctio

212 recovered spontaneously; 10 (50%) underwent orthotopic liver transplantation (OLT), while six (30%)

213 WHVP-IVC (HVPG-IVC), better correlates with orthotopic liver transplantation (OLT)-free survival.

214 tant causes of morbidity and mortality after orthotopic liver transplantation (OLT).

215 has been associated with poor outcomes after orthotopic liver transplantation (OLT).

216 maximum utilization of donor allografts for orthotopic liver transplantation (OLT).

217 (HCV) is now the most common indication for orthotopic liver transplantation (OLT).

218 ve treatment for recurrent hepatitis C after orthotopic liver transplantation (OLT).

219 dies have evaluated long-term outcomes after orthotopic liver transplantation (OLT).

220 uncommon but often fatal complication after orthotopic liver transplantation (OLT).

221 ents with chronic liver disease patients for orthotopic liver transplantation (OLT).

222 eived re-OLT more than 90 days after primary orthotopic liver transplantation (OLT).

223 correlate with the course of infection after orthotopic liver transplantation (OLT).

224 or rabbit antithymocyte globulin (RATG) for orthotopic liver transplantation (OLT).

225 n her sibling, whose liver had been used for orthotopic liver transplantation (OLT).

226 disease (ESLD) and that it increases during orthotopic liver transplantation (OLT).

227 d risk of ischemic heart disease (IHD) after orthotopic liver transplantation (OLT).

228 itively with liver disease progression after orthotopic liver transplantation (OLT).

229 ing FK506 as a part of immunosuppression for orthotopic liver transplantation (OLT).

230 injury in many deleterious complications of orthotopic liver transplantation (OLT).

231 ailure in children, frequently necessitating orthotopic liver transplantation (OLT).

232 to the ICU are often evaluated for possible orthotopic liver transplantation (OLT).

233 rus-(HBV) infected patients before and after orthotopic liver transplantation (OLT).

234 ant murine model of hepatic cold storage and orthotopic liver transplantation (OLT).

235 the morbidity and mortality associated with orthotopic liver transplantation (OLT).

236 r rejection and graft/patient survival after orthotopic liver transplantation (OLT).

237 Solid cancers are a major adverse outcome of orthotopic liver transplantation (OLT).

238 hepatitis occurring de novo after pediatric orthotopic liver transplantation (OLT).

239 bleeding or treat intractable ascites before orthotopic liver transplantation (OLT).

240 and liver injury in pediatric patients after orthotopic liver transplantation (OLT).

241 nt on the development of HA complications in orthotopic liver transplantation (OLT).

242 rahepatic portosystemic shunting (TIPS), and orthotopic liver transplantation (OLT).

243 major cause of morbidity and mortality after orthotopic liver transplantation (OLT).

244 key obstacle to expanding the donor pool in orthotopic liver transplantation (OLT).

245 ) remains an important challenge in clinical orthotopic liver transplantation (OLT).

246 tended hepatic cold preservation followed by orthotopic liver transplantation (OLT).

247 djuvant chemoradiation treatment followed by orthotopic liver transplantation (OLT).

248 brain injury (BI) in ALF patients undergoing orthotopic liver transplantation (OLT).

249 injury remains a major challenge in clinical orthotopic liver transplantation (OLT).

250 en to be a potent immunosuppressive agent in orthotopic liver transplantation (OLT).

251 h hepatocellular carcinoma (HCC) who receive orthotopic liver transplantation (OLT).

252 survival in patients with cirrhosis awaiting orthotopic liver transplantation (OLT).

253 16-46 years (five women, four candidates for orthotopic liver transplantation [OLT]) with acute liver

254 end-stage liver disease who were undergoing orthotopic liver transplantation (OLTX) after the availa

255 major cause of morbidity and mortality after orthotopic liver transplantation (OLTX) and is predomina

256 Fourteen patients underwent orthotopic liver transplantation (OLTx) for PLD between

257 Their use in orthotopic liver transplantation (OLTX) has dramatically

258 Neurological complications after orthotopic liver transplantation (OLTX) have remained a

259 Orthotopic liver transplantation (OLTX) is the treatment

260 Acute renal failure developing after orthotopic liver transplantation (OLTx) requiring renal

261 m creatinine (sCr) <1.0 mg/dL (n=143) before orthotopic liver transplantation (OLTX) were included in

262 patitis (AIH), as an original indication for orthotopic liver transplantation (OLTX), predisposes to

263 ated cirrhosis is the leading indication for orthotopic liver transplantation (OLTx).

264 ate, the risk of brainstem herniation unless orthotopic liver transplantation or spontaneous liver re

265 performed at the last MR examination before orthotopic liver transplantation or surgical resection.

266 cept further alcoholic rehabilitation before orthotopic liver transplantation, P=0.01.

267 tochemistry in allograft biopsy specimens of orthotopic liver transplantation patients with recurrent

268 tion patients, and 14.26 dollars for the non-orthotopic liver transplantation patients).

269 95 dollars in charges (51.03 dollars for the orthotopic liver transplantation patients, and 14.26 dol

270 Four underwent repeat piggyback orthotopic liver transplantation prior to intervention.

271 failure; c) patients immediately status post-orthotopic liver transplantation receiving a steroid-fre

272 Orthotopic liver transplantation remains the only effect

273 Orthotopic liver transplantation remains the only effect

274 Orthotopic liver transplantation remains the only establ

275 ations after OLT, the Cardiovascular Risk in Orthotopic Liver Transplantation risk score, among a coh

276 Sixteen months after orthotopic liver transplantation, she is HBV DNA seroneg

277 at dependency on RRT in the first week after orthotopic liver transplantation stems almost entirely f

278 Orthotopic liver transplantation substantially reduces t

279 After orthotopic liver transplantation, survival, serum transa

280 n of HCV genotypes, the mean follow-up after orthotopic liver transplantation, the mean number of all

281 ation has been proposed as an alternative to orthotopic liver transplantation to treat metabolic live

282 rgical choices in complex procedures such as orthotopic liver transplantation trigger a chain of even

283 A prospective trial in orthotopic liver transplantation using Mycophenolate Mof

284 ence of CMV DNA for the first 12 weeks after orthotopic liver transplantation using the Murex hybrid

285 Orthotopic liver transplantation, using whole or partial

286 We first introduced the orthotopic liver transplantation utilizing cavaplasty te

287 The mean interval between chemotherapy and orthotopic liver transplantation was 111 days (range, 3-

288 col combining neoadjuvant chemoradiation and orthotopic liver transplantation was first used in patie

289 Orthotopic liver transplantation was performed between p

290 the efficacy of hepatocyte transplantation, orthotopic liver transplantation was performed successfu

291 Orthotopic liver transplantation was performed using ste

292 Orthotopic liver transplantation was performed with 18-h

293 provement of intracranial pressure such that orthotopic liver transplantation was undertaken.

294 Using experimental orthotopic liver transplantation, we showed that the eff

295 of Ireland, 606 patients undergoing a first orthotopic liver transplantation were randomly assigned

296 asures of disease severity/progression, like orthotopic liver transplantation, when genetic analyses

297 ho had a hepatic artery pseudoaneurysm after orthotopic liver transplantation, which was successfully

298 of CD39 on liver mDCs in vivo, we performed orthotopic liver transplantation with extended cold pres

299 The standard technique of orthotopic liver transplantation with venovenous bypass

300 expression/activation of MMP-9 in steatotic orthotopic liver transplantations without significantly